The efficacy of
99mTc-rituximab
Melanoma
false negative
radioactive tracer
sentinel node biopsy
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
22
11
2021
accepted:
20
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
ppublish
Résumé
The sentinel lymph node (SLN) status is a vital prognostic factor for malignant melanoma (MM) patients. There is increasing evidence that a radioactive agent, rather than its combination with blue dye, is sufficient for a SLN biopsy (SLNB). Thus, we discussed the efficacy of A total of 502 consecutive patients with MM who underwent SLNB were enrolled in this study. All participants were peritumorally injected with The SLNs were successfully imaged via SPECT-CT and harvested from all 502 participants. No drainage tube was indwelled and 32 (6.3%) participants experienced the following complications: seroma (n=26, 5.2%), wound infections or lymphangitis (n=6, 1.2%), sensory nerve injuries (n=4, 0.8%). There were 380 patients who were diagnosed as SLN-negative and 122 (24.2%) were SLN-positive. A total of 85 SLN-positive patients received complete lymph node dissection, and 28 (32.9%) had additional positive lymph nodes. During a median follow-up of 24 months, 28 participants were found to have a false negative (FN) SLN. The FN rate was 18.7%. A higher T stage was a predictive factor for FN [odds ratio (OR) 1.77; P<0.05]. There was no significant difference in the positive or FN rate between the acral and cutaneous groups. The radiopharmaceutical
Sections du résumé
Background
UNASSIGNED
The sentinel lymph node (SLN) status is a vital prognostic factor for malignant melanoma (MM) patients. There is increasing evidence that a radioactive agent, rather than its combination with blue dye, is sufficient for a SLN biopsy (SLNB). Thus, we discussed the efficacy of
Methods
UNASSIGNED
A total of 502 consecutive patients with MM who underwent SLNB were enrolled in this study. All participants were peritumorally injected with
Results
UNASSIGNED
The SLNs were successfully imaged via SPECT-CT and harvested from all 502 participants. No drainage tube was indwelled and 32 (6.3%) participants experienced the following complications: seroma (n=26, 5.2%), wound infections or lymphangitis (n=6, 1.2%), sensory nerve injuries (n=4, 0.8%). There were 380 patients who were diagnosed as SLN-negative and 122 (24.2%) were SLN-positive. A total of 85 SLN-positive patients received complete lymph node dissection, and 28 (32.9%) had additional positive lymph nodes. During a median follow-up of 24 months, 28 participants were found to have a false negative (FN) SLN. The FN rate was 18.7%. A higher T stage was a predictive factor for FN [odds ratio (OR) 1.77; P<0.05]. There was no significant difference in the positive or FN rate between the acral and cutaneous groups.
Conclusions
UNASSIGNED
The radiopharmaceutical
Identifiants
pubmed: 35282108
doi: 10.21037/atm-21-6890
pii: atm-10-02-95
pmc: PMC8848438
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95Informations de copyright
2022 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-21-6890/coif). All authors report that this study was supported by the Science Foundation of Peking University Cancer Hospital. The authors have no other conflicts of interest to declare.
Références
J Nucl Med. 2016 Aug;57(8):1214-20
pubmed: 26985055
Melanoma Res. 2001 Jun;11(3):303-7
pubmed: 11468520
Ann Surg Oncol. 2000 May;7(4):262-7
pubmed: 10819365
Eur J Surg Oncol. 2002 Sep;28(6):673-8
pubmed: 12359207
Ann Surg Oncol. 2015 Jul;22(7):2120-6
pubmed: 25940571
Eur J Surg Oncol. 2015 Jul;41(7):830-6
pubmed: 25595509
Melanoma Res. 2014 Oct;24(5):454-61
pubmed: 24811213
Melanoma Res. 2004 Aug;14(4):311-9
pubmed: 15305163
Eur J Surg Oncol. 2005 Sep;31(7):778-83
pubmed: 15993029
J Am Acad Dermatol. 2006 Jan;54(1):19-27
pubmed: 16384752
J Am Coll Surg. 2004 Jun;198(6):924-32
pubmed: 15194074
Anticancer Res. 2015 Jan;35(1):301-9
pubmed: 25550564
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
Ann Surg Oncol. 2003 Jul;10(6):676-80
pubmed: 12839853
Ann Surg Oncol. 2002 Nov;9(9):934;author reply 934-5
pubmed: 12417520
Surg Oncol. 2011 Mar;20(1):e55-9
pubmed: 21074413
Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3
pubmed: 16135917
Sci Rep. 2016 Aug 22;6:31432
pubmed: 27545198
Melanoma Res. 2016 Oct;26(5):464-8
pubmed: 27232099
J Plast Reconstr Aesthet Surg. 2018 Sep;71(9):1269-1273
pubmed: 29937368
Eur J Surg Oncol. 2004 Oct;30(8):851-6
pubmed: 15336731
Ann Surg Oncol. 2003 Jun;10(5):569-74
pubmed: 12794025
BMC Cancer. 2011 Feb 25;11:85
pubmed: 21349197
J Int Med Res. 2017 Aug;45(4):1369-1377
pubmed: 28587543
Clin Exp Dermatol. 2004 Nov;29(6):600-4
pubmed: 15550131
Ann Surg Oncol. 2002 Aug;9(7):637-45
pubmed: 12167577
Breast Cancer Res Treat. 2018 Apr;168(2):365-370
pubmed: 29209873
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402
pubmed: 30959471
Surg Clin North Am. 2003 Apr;83(2):275-82
pubmed: 12744610
Cancer. 2015 May 15;121(10):1628-36
pubmed: 25677366
J Am Acad Dermatol. 2018 Oct;79(4):706-713
pubmed: 29673774
Ann Surg Oncol. 2006 Dec;13(12):1655-63
pubmed: 17016755
World J Surg Oncol. 2015 Oct 13;13:299
pubmed: 26462471
Dermatology. 2014;229(3):183-9
pubmed: 25171688
Ann Surg Oncol. 2000 Jun;7(5):361-6
pubmed: 10864344
Cancer. 2001 Jun 15;91(12):2401-8
pubmed: 11413531
Ann Surg Oncol. 2015 Sep;22(9):2978-87
pubmed: 25605514
Ann Acad Med Singap. 2012 Jan;41(1):17-20
pubmed: 22499476
Ann Surg Oncol. 2013 Aug;20(8):2590-9
pubmed: 23504141
Melanoma Res. 2016 Feb;26(1):42-5
pubmed: 26397049
N Engl J Med. 2014 Feb 13;370(7):599-609
pubmed: 24521106
J Plast Reconstr Aesthet Surg. 2013 Sep;66(9):1299-300
pubmed: 23582508
Melanoma Res. 2004 Dec;14(6):521-6
pubmed: 15577324
Ann Surg Oncol. 2014 Sep;21(9):3117-23
pubmed: 24833100
BMJ. 2006 Jun 17;332(7555):1423
pubmed: 16735303
J Surg Oncol. 2006 Aug 1;94(2):94-100
pubmed: 16847917
Indian J Plast Surg. 2013 Jan;46(1):92-7
pubmed: 23960312
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Br J Surg. 2012 Oct;99(10):1396-405
pubmed: 22961519
Ann Surg Oncol. 2004 Mar;11(3):247-58
pubmed: 14993019